Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
First and only PARP inhibitor to improve invasive disease-free survival in patients
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Subscribe To Our Newsletter & Stay Updated
